Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation

While the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1 has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of drug resistance and residual leukemic stem cells remain. To test whether the degradation of BCR-ABL1 kinase could offer improve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res
Autors principals: Burslem, George M., Schultz, Anna Reister, Bondeson, Daniel P., Eide, Christopher A., Stevens, Samantha L. Savage, Druker, Brian J., Crews, Craig M.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6893872/
https://ncbi.nlm.nih.gov/pubmed/31311809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-1236
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars